Leukemia: Clinical Trials

1,708 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1708 completed. 1708 Phase 2, 403 Phase 1, 41 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21708Completed 1708
Phase 1403Completed 403
Phase 341Completed 41

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 1,708 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL
Phase 1 / Phase 2CompletedNational Research Center for Hematology, Russia582024-11-262026-02-09
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 / Phase 2CompletedChongqing Precision Biotech Co., Ltd52024-03-282026-08-05
Venetoclax After TKI to Target Persisting Stem Cells in CML
Venetoclax - Chronic Myeloid Leukemia
Phase 2CompletedThomas Ernst, PD Dr. med.102023-08-312026-08-18
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 - Chronic Lymphocytic Leukemia, COVID-19 Infection
Phase 2CompletedCity of Hope Medical Center472023-08-012026-09-09
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Imetelstat sodium - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 2CompletedGCP-Service International West GmbH462023-06-052026-10-02
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7" - Acute Myeloid Leukemia
Phase 2CompletedChinese PLA General Hospital2002023-03-012026-01-20
Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte - Acute Myeloid Leukemia
Phase 2CompletedChinese PLA General Hospital302022-12-252024-11-08
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
Venetoclax in combination with azacitidine and CAG - Acute Myeloid Leukemia
Phase 2CompletedHematology department of the 920th hospital1142022-12-012025-07-15
Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia
cladribine + homoharringtonine + cytarabine - Acute Myeloid Leukemia, Adult
Phase 2CompletedFirst Affiliated Hospital of Zhejiang University652022-10-262026-02-04
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Liposomal Annamycin, Cytarabine - Leukemia, Myeloid, Acute
Phase 1 / Phase 2CompletedMoleculin Biotech, Inc.222022-09-292025-09-30
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
ABC008 - T-cell Large Granular Lymphocytic Leukemia
Phase 1 / Phase 2CompletedAbcuro, Inc.212022-09-282026-05-06
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)
IPAD, Augmented Reality - Pediatric ALL, Cancer
Phase 2CompletedM.D. Anderson Cancer Center292022-08-192026-01-15
Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia
Phase 2CompletedThe First Affiliated Hospital of Soochow University202022-05-012024-04-25
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
Cyclophosphamide, Mesna, Filgrastim - Myeloid Malignancies, Acute Myeloid Leukemia
Phase 2CompletedM.D. Anderson Cancer Center242022-04-082025-12-19
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
Murine autologous anti-CD19 chimeric antigen receptor T cells - Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse
Phase 2CompletedBeijing Boren Hospital22022-03-242025-05-18
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm
CPX-351 - Acute Myeloid Leukemia, Myeloproliferative Syndrome
Phase 2CompletedFrench Innovative Leukemia Organisation422022-03-232024-10-29
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Low dose vemurafenib plus rituximab - Hairy Cell Leukemia
Phase 2CompletedScripps Health152022-03-022026-04-24
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Enasidenib mesylat dose escalation - Leukemia, Leukemia, Myeloid
Phase 1 / Phase 2CompletedTian Yi Zhang172022-01-122026-09-03
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
asciminib, best available treatment - Leukemia, Chronic Myelogenous
Phase 2CompletedNovartis Pharmaceuticals842021-12-062025-04-18
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
chimeric antigen receptor T cell treatment - T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma
Phase 2CompletedBeijing Boren Hospital552021-12-012025-05-18

Showing 20 of 1708. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (698)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (510)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (452)  ·  Myelodysplastic Syndromes (373)  ·  Lymphoma (272)  ·  Lymphoma, Non-Hodgkin (259)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (228)  ·  Lymphoma, Follicular (217)  ·  Lymphoma, Mantle-Cell (192)  ·  Lymphoma, B-Cell, Marginal Zone (185)  ·  Hodgkin Disease (178)  ·  Lymphoma, Large B-Cell, Diffuse (178)  ·  Burkitt Lymphoma (176)  ·  Multiple Myeloma (159)

Broader conditions

Hemic and Lymphatic Diseases (1708)  ·  Neoplasms by Histologic Type (1704)  ·  Hematologic Diseases (1684)  ·  Neoplasms (1646)  ·  Immune System Diseases (993)  ·  Immunoproliferative Disorders (965)  ·  Lymphoproliferative Disorders (955)  ·  Lymphatic Diseases (952)  ·  Leukemia, Myeloid (927)  ·  Pathological Conditions, Signs and Symptoms (918)  ·  Pathologic Processes (912)  ·  Disease Attributes (892)  ·  Leukemia, Lymphoid (845)  ·  Chronic Disease (837)

Interventions

Cyclophosphamide (274)  ·  Cytarabine (238)  ·  fludarabine phosphate (181)  ·  Rituximab (147)  ·  Filgrastim (132)  ·  Methotrexate (129)  ·  Peripheral Blood Stem Cell Transplantation (125)  ·  Busulfan (118)  ·  Etoposide (112)  ·  fludarabine (108)  ·  Mycophenolic Acid (98)  ·  Cyclosporine (89)  ·  Whole-Body Irradiation (83)  ·  Azacitidine (82)  ·  Tacrolimus (82)

Sponsors

M.D. Anderson Cancer Center (176)  ·  National Cancer Institute (NCI) (107)  ·  Fred Hutchinson Cancer Center (94)  ·  Memorial Sloan Kettering Cancer Center (52)  ·  Novartis Pharmaceuticals (36)  ·  National Heart, Lung, and Blood Institute (NHLBI) (24)  ·  Mayo Clinic (23)  ·  Alliance for Clinical Trials in Oncology (22)  ·  Masonic Cancer Center, University of Minnesota (21)  ·  H. Lee Moffitt Cancer Center and Research Institute (20)  ·  Children's Oncology Group (19)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (19)  ·  Case Comprehensive Cancer Center (18)  ·  Bristol-Myers Squibb (17)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (17)

Countries

United States (1249)  ·  Germany (163)  ·  Italy (135)  ·  France (132)  ·  Canada (131)  ·  United Kingdom (96)  ·  Spain (78)  ·  Australia (66)  ·  Belgium (48)  ·  South Korea (48)  ·  Austria (47)  ·  Netherlands (47)  ·  Poland (43)  ·  China (41)  ·  Japan (40)

Top investigators

Brenda Sandmaier (13)  ·  Jorge Cortes, MD (12)  ·  Farhad Ravandi-Kashani, MD (9)  ·  Guillermo Garcia-Manero, MD (8)  ·  Kyoo H. Lee, MD (7)  ·  Elias Jabbour, MD (6)  ·  Hagop Kantarjian, MD (6)

Results publications

PMID 32499241, PMID 23524640, PMID 23065508, PMID 34515338, PMID 35622074, PMID 27209293, PMID 29358183, PMID 30062662, PMID 36184192, PMID 23620574, PMID 25361995, PMID 28835440, PMID 30885996, PMID 31171508, PMID 33242441, PMID 35235189, PMID 17715389, PMID 18596230, PMID 18997171, PMID 19667400, PMID 21403127, PMID 21527516, PMID 21623761, PMID 22133778, PMID 22430088, PMID 23547837, PMID 23886836, PMID 24383844, PMID 24862638, PMID 25527568, PMID 26182309, PMID 26813675, PMID 27355533, PMID 28877686, PMID 29437592, PMID 29618479, PMID 29702001, PMID 30028037, PMID 31023700, PMID 31196847, PMID 32209572, PMID 33394722, PMID 33496754, PMID 33917201, PMID 34048072, PMID 34353848, PMID 34398557, PMID 34432863, PMID 35007144, PMID 35422096

NIH funding

P30CA015704 (41), U10CA031946 (32), P30CA006973 (18), P30CA015083 (17), U10CA032102 (16), P01CA018029 (14), 2008 (13), P30CA043703 (13), 2005 (12), 2009 (12), 2015 (12), P30CA016672 (12), U10CA098543 (11), 2016 (10), U01CA070095 (10)